Research programme: non-acetylated salicylates - Acorda TherapeuticsAlternative Names: CMS
Latest Information Update: 30 Jul 2009
At a glance
- Originator Neurorecovery
- Class Salicylates
- Mechanism of Action Prostaglandin synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation; Neuropathic pain
Most Recent Events
- 05 Feb 2008 Acorda Therapeutics acquires ownership of CM-Sal™ product from Neurorecovery